HUTCHMED (China) - ADR Peer Comparison
$13.85
$-0.42
(-2.94%)
As on 27-Oct-2026 16:00EDT
Market cap
$2,496 Mln
Revenue (TTM)
$549 Mln
P/E Ratio
143.6
P/B Ratio
2.3
Div. Yield
0 %
Edit
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,496 | 2,698 | 1,595 | 793 | 666 |
Revenue ($ Mln) |
549 | 450 | 121 | 366 | 4 |
Net Profit ($ Mln) |
17.88 | -188.21 | -57.76 | 9.27 | -187.89 |
Net Margin (%) |
3.26 | -41.86 | -47.60 | 2.53 | -4,613.11 |
RoE (%) |
1.43 | -28.46 | -9.91 | 3.39 | -233.88 |
Price to Earnings |
143.60 | -- | -- | 86.15 | -- |
Price-To-Book |
2.25 | 4.56 | 3.65 | 2.95 | 19.54 |
Income Statement ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Operating Revenue
|
549.12 | 449.61 | 120.79 | 366.45 | 4.07 |
|
Cost of Revenue
|
548.01 | 195.71 | 19.21 | 49.36 | 47.72 |
|
Gross Profit
|
212.72 | 269.08 | 12.07 | 330.63 | -2.69 |
|
Operating Expenses
|
35.89 | 517.90 | 154.86 | 304.74 | 154.75 |
|
Operating Profit (EBIT)
|
-34.78 | -264.00 | -118.11 | 12.35 | -196.52 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
20.08 | -190.72 | -57.14 | 15.84 | -187.89 |
|
Provision for Tax
|
1.66 | -2.51 | 0.62 | 6.57 | 0.00 |
|
Profit after Tax (Net Income)
|
17.88 | -188.21 | -57.50 | 9.27 | -187.89 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,260.78 | 607.04 | 568.41 | 270.49 | 39.81 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
186.25 | 39.17 | 123.56 | 104.25 | 177.54 |
|
Current Liabilities
|
275.21 | 428.58 | 81.11 | 93.25 | 31.69 |
|
Total Liabilities
|
1,753.10 | 1,172.38 | 784.68 | 499.81 | 342.73 |
Assets ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
183.02 | 160.76 | 575.59 | 187.30 | 152.24 |
|
Current Assets
|
1,553.41 | 914.04 | 197.49 | 280.69 | 96.80 |
|
Total Assets
|
1,753.10 | 1,172.38 | 784.68 | 499.81 | 342.73 |
|
Total Debt*
|
94.51 | 254.58 | 127.33 | 113.30 | 112.48 |
|
Net Current Assets
|
0.00 | 485.45 | 116.38 | 187.44 | 65.11 |
Cashflow ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-64.66 | -150.79 | -49.95 | 54.71 | -162.56 |
|
Cash Flow from Investing Activities
|
-29.41 | 307.87 | 0.12 | 26.25 | -108.76 |
|
Cash from Financing Activities
|
7.84 | 72.35 | 147.34 | 1.50 | 151.51 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
ROCE (%)
|
41.92 | -18.15 | -15.42 | 0.77 | -93.29 |
|
ROE (%)
|
1.43 | -28.46 | -10.06 | 3.39 | -233.88 |
|
ROA (%)
|
0.66 | -12.55 | -6.60 | 1.69 | -63.28 |
|
EBIT Margin (%)
|
-6.33 | -41.09 | -42.43 | 8.34 | -4,613.11 |
|
Net Margin (%)
|
3.26 | -41.86 | -47.60 | 2.53 | -4,613.11 |
|
Cash Profit Margin (%)
|
-- | 0.00 | -- | 0.00 | 0.00 |
Growth Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-8.81 | 5.10 | 602.33 | -99.61 | -17.90 |
|
EBIT Growth (%)
|
-76.55 | 11.36 | 17.93 | 523.06 | 5.71 |
|
Net Profit Growth (%)
|
-96.17 | 11.44 | 43.71 | -99.68 | 5.71 |
|
EPS Growth (%)
|
-96.17 | -1.87 | 47.43 | -96.78 | 28.69 |
|
Book Value Growth (%)
|
2.54 | -25.05 | -6.65 | 7.71 | -52.32 |
Valuation Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.08 | -11.11 | -13.58 | 469.58 | -2.57 |
|
Price / Book Value
|
1.88 | 2.73 | 2.32 | 4.83 | 4.27 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-25.56 | -9.39 | -18.38 | 36.65 | -2.32 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.19 | 0.34 | 0.00 |
|
Short term debt to equity ratio
|
0.02 | 0.40 | 0.02 | 0.03 | 0.23 |
|
Current Ratio
|
5.64 | 2.13 | 2.43 | 3.01 | 3.05 |
|
Quick Ratio
|
5.50 | 1.92 | 2.09 | 2.31 | 3.05 |
|
Interest Coverage
|
-19.05 | -30.87 | -4.06 | 2.08 | -- |
Operating Efficiency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | Prime Medicine | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.41 | 16.23 | 47.25 | 15.55 | 0.00 |
|
Asset Turnover
|
0.20 | 0.30 | 0.14 | 0.67 | 0.01 |
|
Receivable days
|
104.79 | 77.60 | 380.35 | 51.78 | -- |
|
Inventory Days
|
49.57 | 109.55 | 791.94 | 492.02 | -- |
|
Payable days
|
47.68 | 231.78 | 931.00 | 466.91 | 504.84 |
|
Cash Conversion Cycle
|
106.67 | -44.63 | 241.30 | 76.89 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
